These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21847886)

  • 1. Can speech by FDA-regulated firms ever be noncommercial?
    Cortez N
    Am J Law Med; 2011; 37(2-3):388-421. PubMed ID: 21847886
    [No Abstract]   [Full Text] [Related]  

  • 2. Major issues in marketing regulation.
    Pines WL
    Food Drug Law J; 1997; 52(3):297-302. PubMed ID: 10343028
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

  • 5. Off-label drug use and promotion: balancing public health goals and commercial speech.
    Kesselheim AS
    Am J Law Med; 2011; 37(2-3):225-57. PubMed ID: 21847880
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulation of pharmacoeconomics and outcomes research.
    Radensky P
    Value Health; 2001; 4(1):12-5. PubMed ID: 11704968
    [No Abstract]   [Full Text] [Related]  

  • 7. Off-label promotion: government theories of prosecution and facts that drive them.
    Burroughs AD; Levy MC; Schwab GG; Paik Y
    Food Drug Law J; 2010; 65(3):555-88. PubMed ID: 24479242
    [No Abstract]   [Full Text] [Related]  

  • 8. A defense of the learned intermediary doctrine.
    Goetz RB; Growdon KR
    Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
    [No Abstract]   [Full Text] [Related]  

  • 9. Which prescription for the illegible and unreadable DTC (direct-to-consumer) brief summary--major surgery or euthanasia?
    Hochhauser M
    Manag Care Q; 2002; 10(3):6-10. PubMed ID: 12476659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
    Strawn MN
    J Contemp Health Law Policy; 2003; 19(2):495-520. PubMed ID: 14748255
    [No Abstract]   [Full Text] [Related]  

  • 11. The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of Pharmaceuticals.
    Greene JA; Watkins ES
    N Engl J Med; 2015 Sep; 373(12):1087-9. PubMed ID: 26287749
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of direct-to-consumer advertising.
    Navarro RP
    Manag Care Interface; 1998 Nov; 11(11):79-80, 82. PubMed ID: 10187419
    [No Abstract]   [Full Text] [Related]  

  • 13. To inform or persuade? Direct-to-consumer advertising of prescription drugs.
    Berndt ER
    N Engl J Med; 2005 Jan; 352(4):325-8. PubMed ID: 15673797
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug and device litigation in the 21st century.
    Svitak LS; Goss PJ
    Spec Law Dig Health Care Law; 2001 Nov; (271):9-36. PubMed ID: 11802352
    [No Abstract]   [Full Text] [Related]  

  • 15. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
    Green W
    Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
    [No Abstract]   [Full Text] [Related]  

  • 16. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulation of prescription drug promotion: direct-to-consumer advertising.
    Baylor-Henry M; Drezin NA
    Clin Ther; 1998; 20 Suppl C():C86-95. PubMed ID: 9915094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 19. Off-label prescription advertising, the FDA and the First Amendment: a study in the values of commercial speech protection.
    Klasmeier C; Redish MH
    Am J Law Med; 2011; 37(2-3):315-57. PubMed ID: 21847884
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA tightens rules on advertising.
    Josefson D
    BMJ; 1997 Aug; 315(7106):447. PubMed ID: 9284658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.